Patent ID: 6605642
Filing Date: 2003-08-12
Classification: A23L,A61K,A61P

Abstract:
A method of inhibiting formation of glycation endproducts or protein crosslinking in an organism, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:LR93: 1-[4-chlorophenoxyisobutyrylamido]1-cyclohexane carboxylic acid, LR94: DL-4-(3,5-dichlorophenylureidophenoxyisobutyrylpiperdine)-2-carboxylic acid, LR95: L-4-(3,5-dichlorophenylureidophenoxyisobutyryl) leucine, LR96: L-4-(3,5-diclorophenylureidophenoxyisobutyryl) glutamic acid gamma methyl ester, LR97: gamma-4-(3,5-dichlorophenylureidophenoxyisobutyrylamido) butyric acid, LR98: 4-(3,5-dichlorophenylureidophenoxyisobutyrylamido) acetic acid, LR99: 4-(3,5-dichlorophenylureidophenoxyisobutyryl)-4 amino benzoic acid, LR100: 1,4-(3,5-dichlorophenylureidophenoxyisobutyrylamido)-1-cyclopentane carboxylic acid, LR101: 1,4-benzene-bis-(ureidophenoxyisobutyric acid), and LR102: 1,4-benzene-bis-(4-methyleneaminophenoxyisobutyric acid).